The drug’s mechanism of action, targeting the IL-4/IL-13 pathway, is particularly relevant to EoE pathophysiology, as these cytokines play crucial roles in tissue remodeling and eosinophil recruitment [37]. The gene discussed is IL4; the disease is eosinophilic esophagitis.